Učitavanje...
Improving the Efficacy of Radioimmunotherapy for Non-Hodgkin’s Lymphomas
Approximately 66,000 Americans develop non-Hodgkin’s lymphomas (NHL) each year. Although the use of unlabeled antibodies such as rituximab has significantly improved survival when combined with standard chemotherapy regimens, two-thirds of lymphoma patients eventually relapse and succumb to their di...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2820155/ https://ncbi.nlm.nih.gov/pubmed/20127945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24801 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|